Q1 Earnings vs. Estimates
-
EPS: Reported $1.79, beating the $1.67 consensus by $0.12.
-
Revenue: $9.89 B vs. $10.99 B estimate—a 10% shortfall.
-
Key Drivers: Specialty care and vaccines drove margin strength, but generics and consumer health underperformed.
Stock Performance and Analyst Sentiment
-
Closing Price: $53.02 per ADR
-
Momentum: +1.0% over 3 months; +7.4% over 12 months
-
Analyst Revisions: Mixed—positive EPS revisions offset by cautious revenue outlook tweaks.
Financial Health Snapshot
Sanofi’s robust balance sheet underpins its resilience:
-
Profit Margins: Holding up despite top-line pressures
-
Leverage: Moderate debt with ample liquidity
Outlook and Investor Takeaways
-
Q2 Guidance: Look for updated sales forecasts on May 7 earnings call.
-
Pipeline Catalysts: Late-stage readouts in diabetes and immunology.
-
Cost Synergies: Progress on recent M&A integrations could bolster margins.
Track Sanofi’s Past Earnings and Market Reactions
For detailed historical EPS and revenue surprises—and how Sanofi’s stock reacted—use the
🔗 Historical Earnings API
from Financial Modeling Prep. This API delivers past earnings versus estimates, enabling you to analyze patterns in consensus beats, misses, and stock price responses.
